Clinical Trial Update: Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 follow-on study of the AAV2-hRPE65v2 gene therapy vector for Leber congenital amaurosis (LCA2) is ongoing. The sponsor Spark Therapeutics reports th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis

Drugs mentioned

• AAV2-hRPE65v2 vector

Snippet

Sponsor: Spark Therapeutics, Inc. | Conditions: Leber Congenital Amaurosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING